🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On Memorial Day, we pause to honor the bravery of those who stepped forward to serve. Your strength, service, and sacrifice will never be forgotten.

We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield™ platform to Saudi Arabia and the broader Middle East. Learn more: immunitybio.com/immunitybio-sa…

Our dedication fuels breakthrough innovations, aiming to improve outcomes for all patients. Learn more about our founder's vision: immunitybio.com/founders-visio…

As Bladder Cancer Awareness Month concludes, our hearts remain with those affected. ImmunityBio is committed to advancing care and supporting patients every step of the way.

We've announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of our Cancer BioShield™ platform, anchored by ANKTIVA®, to treat lymphopenia in adult patients with refractory or relapsed solid tumors who have progressed

ImmunityBio, Inc. receives FDA Expanded Access Authorization for landmark treatment of lymphopenia with ANKTIVA®, the cancer BioShield™ Platform, in patients with solid tumors. #ReadNow details on UroToday > bit.ly/3HA5iR8 Dr. Pat Soon-Shiong #ASCO25

At ImmunityBio, we're redefining cancer care. Our mission focuses on developing treatments that are not only effective, but also aim to enhance patient comfort. Our team works to improve the experiences of those undergoing cancer treatment, offering hope through innovative

x.com/i/article/1931…

The power of natural killer cells (NK cells) - Nature's first responder to cancer and infection. The Cancer Bioshield enables your body to be the factory and protect the immune system that matters. See the X article posted today. x.com/DrPatSoonShion…

Lynch syndrome affects an estimated 1 in 279 in the U.S., emphasizing the importance of awareness and early detection in order to prevent cancers like colon cancer. ImmunityBio’s investigational study aims to improve outcomes for those affected. Learn more:

There is a biologic for anemia: EPOGEN. And one for neutropenia: NUEPOGEN. But never in the history of medicine one for Lymphopenia, the NK and T cells that matter! Now there is. NCT# to enable access to physicians and patients who need it. Cancer Bioshield

Advanced ovarian cancer presents significant challenges, especially for this with platinum-resistant recurrence. ImmunityBio is working on potential solutions through our clinical trial for recurrent platinum-resistant high-grade ovarian cancer. Our goal is to provide new hope

At ImmunityBio, our commitment to innovation drives us to explore new frontiers in medicine. From addressing genetic disorders like Lynch syndrome to tackling complex cancers such as bladder cancer, we are dedicated to making a meaningful impact. Join us in our journey to

Papillary non-muscle invasive #BladderCancer treatment guidelines gap. Dr. Pat Soon-Shiong ImmunityBio, Inc. joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss expanding ANKTIVA® (NAI) use to include papillary-only BCG-unresponsive bladder cancer. 📊 82% bladder preservation at 36 months 🧬

"Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio, we're working to transform how cancer is treated by designing therapies that not only target disease, but restore the body's natural ability to fight it. View

Absolute lymphocyte count and neutrophil-to-lymphocyte ratios: Overlooked biomarkers in cancer treatment outcomes. Dr. Pat Soon-Shiong ImmunityBio, Inc. and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center discuss research across multiple tumor types showing that patients maintaining ALC above 1,500 have

Annually, over 230,000 people in the United States are diagnosed with lung cancer, with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells, empowering the immune system to better combat NSCLC. Learn more about our

We are happy to share that, as a proud sponsor of the SITC event at Buddy Guy’s Legends, we helped raise over $60,000 through the Forward Fund. These funds will directly support the programs, awards, and grants that advance the professional development of investigators, ensuring

Recombinant BCG addressing #BladderCancer treatment shortages. Dr. Pat Soon-Shiong ImmunityBio, Inc. joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access

Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science